<p><strong>Processa Pharmaceuticals</strong>（納斯達克股票代碼：<strong>PCSA</strong>）股價在週二上漲，此前公司發佈了美國食品藥品監督管理局（FDA）的最新消息。</p>
<p>FDA 已經批准 Processa Pharmaceuticals 進行第二階段臨牀試驗 Next Generation Capecitabine（NGC-Cap）。這是該公司的主力產品候選藥物，旨在治療晚期或轉移性乳腺癌患者。</p>
<p>憑藉這一批准，Processa Pharmaceuticals 得以推進 NGC-Cap 的臨牀試驗。該公司表示，他們預計本季度將開始招募參與該研究的患者。</p>
<p>Processa Pharmaceuticals 研發總裁 David Young 對 NGC-Cap 發表瞭如下看法。</p>
<p>“我們先前在第 1b 階段研究中證明，NGC-Cap 比單藥卡培他濱更有效，使癌細胞暴露於 5-氟尿嘧啶的濃度提高了 5-10 倍。這種更高的暴露導致了更高的療效，同時安全性優於或類似於現有的單藥卡培他濱。”</p>
<h2>今日 PCSA 股票走勢</h2>
<p>隨着這一消息的傳出，PCSA 股票今天交投活躍。截至目前，成交量已超過 5100 萬股。與該公司日均成交量約為 9 萬股相比，這是一次巨大的漲勢。</p>
<p>截至週二上午，PCSA 股價上漲了 29.4%。</p>
<p>尋找更多最新股市新聞的投資者們請繼續關注！</p>
<p>我們將為投資者提供有關週二需瞭解的所有最熱門股市新聞！一些例子包括今天 <strong>特斯拉</strong>（納斯達克股票代碼：<strong>TSLA</strong>）、<strong>達美航空</strong>（紐約證券交易所股票代碼：<strong>DAL</strong>）和 <strong>SoFi</strong>（納斯達克股票代碼：<strong>SOFI</strong>）股票的最新動態。所有這些新聞都可以通過以下鏈接查看！</p>
<h2>週二更多股市新聞</h2>
<ul>
<li>特斯拉股價下跌，因召回 180 萬輛電動汽車涉及引擎蓋問題</li>
<li>達美航空股票：達美要求 CrowdStrike 賠償因故障導致的航班延誤</li>
<li>SoFi 股票：SoFi 再次提高盈利預期。發生了什麼？</li>
</ul>
<p>_<strong>關於低價股和低交易量股票：</strong> 除了極少數例外，InvestorPlace 不會發表關於市值低於 1 億美元或每日交易量低於 10 萬股的公司的評論。這是因為這些 “低價股” 經常成為騙子和市場操縱者的活動場所。如果我們確實發表了可能受到我們評論影響的低交易量股票的評論，我們要求 InvestorPlace.com 的撰稿人披露這一事實，並警告讀者存在的風險。</p>
<p><em><strong>閲讀更多：</strong> 低價股 —</em> <em>如何獲利而不受騙</em></p>
<p><em>在本文發佈日期，William White 對本文提及的證券沒有（直接或間接）任何持倉。本文中表達的觀點屬於作者個人，受 InvestorPlace.com</em> <em>發佈準則</em> <em>約束。</em></p>

PCSA

<p>Processa Pharmaceuticals（納斯達克股票代碼：PCSA）股價上漲了 29.4%，原因是獲得了美國食品和藥物管理局（FDA）對其第二階段臨牀試驗 Next Generation Capecitabine（NGC-Cap）的許可，該藥物用於治療晚期或轉移性乳腺癌。該公司預計本季度開始招募患者。股票交易激增，超過 5100 萬股交易，而日均交易量為 9 萬股</p>

<p><strong>Processa Pharmaceuticals</strong> (NASDAQ: <strong>PCSA</strong>) stock is rising higher on Tuesday after the company posted an update from the Food and Drug Administration (FDA).</p>
<div class="lb-trans"><p><strong>Processa Pharmaceuticals</strong>（納斯達克股票代碼：<strong>PCSA</strong>）股價在週二上漲，此前公司發佈了美國食品藥品監督管理局（FDA）的最新消息。</p>
</div><p>The FDA has cleared Processa Pharmaceuticals for its Phase 2 clinical trial Next Generation Capecitabine (NGC-Cap). This is the company’s lead product candidate and is designed to treat patients with advanced or metastatic breast cancer.</p>
<div class="lb-trans"><p>FDA 已經批准 Processa Pharmaceuticals 進行第二階段臨牀試驗 Next Generation Capecitabine（NGC-Cap）。這是該公司的主力產品候選藥物，旨在治療晚期或轉移性乳腺癌患者。</p>
</div><p>With this approval, Processa Pharmaceuticals is able to move forward with a clinical trial of NGC-Cap. The company says that it expect to start enrolling patients in this study this quarter.</p>
<div class="lb-trans"><p>憑藉這一批准，Processa Pharmaceuticals 得以推進 NGC-Cap 的臨牀試驗。該公司表示，他們預計本季度將開始招募參與該研究的患者。</p>
</div><p>David Young, president of research and development at Processa Pharmaceuticals, said this about NGC-Cap.</p>
<blockquote>
</blockquote>
<div class="lb-trans"><p>Processa Pharmaceuticals 研發總裁 David Young 對 NGC-Cap 發表瞭如下看法。</p>
</div><p>“We previously demonstrated in our Phase 1b study that NGC-Cap is more potent than monotherapy capecitabine, providing up to 5-10 times more 5-fluorouracil exposure to cancer cells. This greater exposure resulted in a greater efficacy, with a safety profile better or similar to existing monotherapy with capecitabine.”</p>
<div class="lb-trans"><p>“我們先前在第 1b 階段研究中證明，NGC-Cap 比單藥卡培他濱更有效，使癌細胞暴露於 5-氟尿嘧啶的濃度提高了 5-10 倍。這種更高的暴露導致了更高的療效，同時安全性優於或類似於現有的單藥卡培他濱。”</p>
</div><h2>PCSA Stock Movement Today</h2>
<div class="lb-trans"><h2>今日 PCSA 股票走勢</h2>
</div><p>With all of this comes heavy trading of PCSA stock today. That has more than 51 million shares changing hands as of this writing. This is a massive surge compared to the company’s daily average trading volume of about 90,000 shares.</p>
<div class="lb-trans"><p>隨着這一消息的傳出，PCSA 股票今天交投活躍。截至目前，成交量已超過 5100 萬股。與該公司日均成交量約為 9 萬股相比，這是一次巨大的漲勢。</p>
</div><p>PCSA stock is up 29.4% as of Tuesday morning.</p>
<div class="lb-trans"><p>截至週二上午，PCSA 股價上漲了 29.4%。</p>
</div><p>Investors seeking out even more of the most recent stock market stories are going to want to stick around!</p>
<div class="lb-trans"><p>尋找更多最新股市新聞的投資者們請繼續關注！</p>
</div><p>We are offering up insight into all of the hottest stock market news that investors need to know about on Tuesday! A few examples include what’s happening with shares of <strong>Tesla</strong>(NASDAQ: <strong>TSLA</strong>), <strong>Delta</strong> (NYSE: <strong>DAL</strong>) and <strong>SoFi</strong> (NASDAQ: <strong>SOFI</strong>) stock today. All of that news is ready to go at the links below!</p>
<div class="lb-trans"><p>我們將為投資者提供有關週二需瞭解的所有最熱門股市新聞！一些例子包括今天 <strong>特斯拉</strong>（納斯達克股票代碼：<strong>TSLA</strong>）、<strong>達美航空</strong>（紐約證券交易所股票代碼：<strong>DAL</strong>）和 <strong>SoFi</strong>（納斯達克股票代碼：<strong>SOFI</strong>）股票的最新動態。所有這些新聞都可以通過以下鏈接查看！</p>
</div><h2>More Stock Market News for Tuesday</h2>
<ul>
<li>TSLA Stock Drops as Tesla Recalls 1.8 Million EVs Over Hood Issue</li>
<li>DAL Stock: Delta Wants CrowdStrike to Pay Up for Flight Delays Caused by Outage</li>
<li>SOFI Stock: SoFi Just Raised Its Profit Guidance Again. What’s Going On?</li>
</ul>
<div class="lb-trans"><h2>週二更多股市新聞</h2>
<ul>
<li>特斯拉股價下跌，因召回 180 萬輛電動汽車涉及引擎蓋問題</li>
<li>達美航空股票：達美要求 CrowdStrike 賠償因故障導致的航班延誤</li>
<li>SoFi 股票：SoFi 再次提高盈利預期。發生了什麼？</li>
</ul>
</div><p><em><strong>On Penny Stocks and Low-Volume Stocks:</strong> With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.</em></p>
<div class="lb-trans"><p>_<strong>關於低價股和低交易量股票：</strong> 除了極少數例外，InvestorPlace 不會發表關於市值低於 1 億美元或每日交易量低於 10 萬股的公司的評論。這是因為這些 “低價股” 經常成為騙子和市場操縱者的活動場所。如果我們確實發表了可能受到我們評論影響的低交易量股票的評論，我們要求 InvestorPlace.com 的撰稿人披露這一事實，並警告讀者存在的風險。</p>
</div><p><em><strong>Read More:</strong> Penny Stocks —</em> <em>How to Profit Without Getting Scammed</em></p>
<div class="lb-trans"><p><em><strong>閲讀更多：</strong> 低價股 —</em> <em>如何獲利而不受騙</em></p>
</div><p><em>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com</em> <em>Publishing Guidelines</em> <em>.</em></p>
<div class="lb-trans"><p><em>在本文發佈日期，William White 對本文提及的證券沒有（直接或間接）任何持倉。本文中表達的觀點屬於作者個人，受 InvestorPlace.com</em> <em>發佈準則</em> <em>約束。</em></p>
</div>

為什麼 Processa Pharmaceuticals（PCSA）的股票今天上漲了 29%？